Research
Hormonal
SGLT2 inhibitors reduce cardiovascular disease risk and mortality in Type 2 Diabetes patients, but are associated with increased risks of urogenital infections, dehydration, hypotension, osteoporotic fractures, and limb amputation.
SGLT2 inhibitors offer significant cardiovascular benefits but require caution in elderly patients and those with kidney disease due to risks of dehydration, hypotension, and infections. Monitor for signs of these side effects.
GoodQualifiesHIGH confidence
The use of sodium-glucose cotransporter 2 (SGLT2) inhibitors has recently led to a significant reduction in the risk of cardiovascular disease and mortality in patients with diabetes... However, due to possible side effects such as urogenital infection, dehydration, and hypotension... A recent multi-center, prospective, randomized controlled clinical trial has reported an increased risk of osteoporotic fractures and limb amputation associated with the use of this medication
Why this rating
Based on multicenter prospective randomized controlled trials.
Source
Monotherapy in Patients with Type 2 Diabetes Mellitus
Sang Youl Rhee et al. · Diabetes & Metabolism Journal · 2017
DOI 10.4093/dmj.2017.41.5.349
clinical_guidelineCited 19×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Metformin is the preferred initial oral hypoglycemic agent for Type 2 Diabetes Mellitus due to its excellent blood glucose-lowering effect, relatively low side effects, long-term safety, low risk of hypoglycemia, and low weight gain.Good
- DPP4 inhibitors are effective substitutes for metformin with low hypoglycemia risk, but their cardiovascular effects are neutral and they may slightly increase heart failure risk.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →